Hospira HSP
-
New Morningstar Analyst Report - Hospira , Inc.
… consent decree. A 2013 patent expiration on Hospira 's branded anesthetic, Precedex, and ..... the company's profitability.Sales of Hospira 's medical devices should remain depressed until hospital spending improves. Hospira 's international growth should lag that …
-
Shares of Hospira ([[HSP]] -1.4%) dip after the company announced a voluntary recall over the weekend of one lot of its Hydromorphone Injection due to two reported complaints of a single Carpuject ...
Shares of Hospira ( HSP -1.4% ) dip after the company announced a voluntary recall over the weekend of one lot of its Hydromorphone Injection …
-
New Morningstar Analyst Report - Teva Pharmaceutical Industries, Ltd.
… marketing these drugs will limit competition and uphold profitability for the successful contenders. Along with Novartis and Hospira HSP, Teva is one of the three major biosimilar competitors in Europe. While the U.S. biosimilar approval guidelines are …
-
Hospira's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Hospira ( HSP ) Q1 2012 Earnings Call May 01, 2012 9:00 am ET Executives Karen King - F. Michael Ball - Chief Executive Officer, Director …
-
UPDATE 1- Hospira results beat estimates
May 1 (Reuters) - Specialty medicines maker Hospira Inc posted a quarterly profit that beat market estimates on strong sales at its Europe, Middle East and Africa region.
-
Hospira (HSP): Q1 EPS of $0.47 beats by $0.01. Revenue of $966M (-3.6% Y/Y) beats by $17M. (PR)
Hospira ( HSP ): Q1 EPS of $0.47 beats by $0.01 . Revenue of $966M (-3.6% Y/Y) beats by $17M . ( PR ) Post your comment!
-
Despite Hospira's Regulatory Uncertainty, Positives Emerge
Hospira HSP reported first-quarter results that ..... s ongoing manufacturing woes. Sales in Hospira 's specialty pharmaceuticals segment slid ..... approximately $2.15. While we admit that Hospira continues to face significant near-term …
-
Hospira , Inc. HSP Q1 2012 Earnings Call Transcript
Welcome to Hospira 's First Quarter 2012 Conference Call. All lines have been placed on listen-only mode to prevent any background noise. Following …
-
Sanofi Could Plunge This Year On New Legal Pitfalls
… price of around $36. 'Aventis Pharma S.A. v. Hospira , Inc ' and Other Legal Potholes Sanofi's downturn in the ..... Rituxan and Avastin, as well as its lost suit against Hospira ( HSP) and Apotex over the cancer drug Taxotere. Recently …
-
New Morningstar Analyst Report for Momenta Pharmaceuticals, Inc.
… Amphastar (through a partnership with Watson) became the second company to receive a generic Lovenox approval while Teva TEVA and Hospira HSP still have pending applications. Depending on European clinical trial requirements, Momenta and others should soon launch …